WASHINGTON — Congress’ Medicare advisers are chiding lawmakers for a controversial change they made to the Medicare prescription drug program’s so-called donut hole last year.

The group, known as MedPAC, argued in its annual report Friday that the change — which puts drug makers, rather than insurers, on the hook for a higher percentage of the cost of some Medicare drugs — disincentivizes insurance companies from managing high drug costs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This donut hole problem is another perfect example of how the PBM’s are to blame. Medicare part D patients are charged AWP. By doing this the patient goes into the donut hole so much quicker.Once the patient is in the donut hole they pay 100% of the cost until they get out of the donut hole. The problem is that the patient never spends enough on drugs to get out of the hole. The PBM would never let the pharmacy keep that AWP money(they know what the drug cost) . So a month later the PBM claws back the difference between AWP and what the drug costs. These claw backs are called D.I.R fees. A Harvard law professor would never be able to figure out how these PBM’s came up with this bunch of crap method of stealing .This donut hole problem is another way the PBM’s are making billions of dollars,and not allowing the mom & pop pharmacy to survive .
    Does anyone else see a problem with the PBM’s ? or is it just me ?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy